ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Sartorius (SRT3.XETRA)
Sartorius stock price today, ATLAS forecast and fair value
Healthcare · Medical Instruments & Supplies · Xetra (Deutsche Börse) · Germany
€290.70▲ +0.41%
Prices as of Oct 27, 2026 · EUR
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Sartorius in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Sartorius
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Sartorius a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €273.18 and €309.56; in 9 out of 10, between €244.52 and €345.84. Estimated annual volatility is 34%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- €17.9B
- Market cap (USD)
- $19.9B
- P/E ratio
- 102.2
- Dividend yield
- 0.26%
- 52-week high
- €291.80
- 52-week low
- €198.50
- Revenue (12 months)
- €3.7B
- Gross margin
- 45.4%
- Operating margin
- 17.9%
- Net margin
- 6.0%
- Beta
- 1.45
What this means
ATLAS does not publish a fair value for SRT3.XETRA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SRT3.XETRA has traded between €198.50 and €291.80. Today it is at its high and 46% above its low.
On the business: net margin is 6.0%; it trades at 102.2 times earnings.
Its beta is 1.45: it tends to move more than the market, both up and down.
About the company
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide.
Want to see everything about Sartorius?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Sartorius do?
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide.
What is the chance SRT3.XETRA goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, SRT3.XETRA ends the month between €273.18 and €309.56.
How big is Sartorius and what is its P/E ratio?
Sartorius's market capitalization is €17.9B. Its price-to-earnings (P/E) ratio is 102.2: you pay €102.2 for each €1.00 of yearly earnings.
Does Sartorius pay a dividend?
Yes. SRT3.XETRA's current dividend yield is 0.26% at today's price (€290.70).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer